BRIEF published on 09/12/2025 at 17:50, 1 year ago Abivax Joins CAC Mid 60 and SBF 120 Indices Euronext Paris Biotechnology Abivax SBF 120 CAC Mid 60
PRESS RELEASE published on 09/12/2025 at 17:45, 1 year ago Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review Abivax to join CAC Mid 60 and SBF 120 Indices on Euronext Paris following annual review, enhancing visibility and investor base Euronext Paris Abivax SBF 120 Index Inclusion CAC Mid 60
BRIEF published on 09/08/2025 at 22:05, 1 year ago Abivax Reports First Half 2025 Financial Performance Financial Results Research And Development Convertible Notes Public Offering Cash Reserves
PRESS RELEASE published on 09/08/2025 at 22:00, 1 year ago Abivax Presents First Half 2025 Financial Results Abivax presents first half 2025 financial results, revealing operating loss increase and net loss for the period, also updates on clinical programs and public offering Financial Results Abivax Public Offering Clinical Programs Operating Loss
BRIEF published on 09/02/2025 at 11:00, 1 year ago JP Morgan Chase & Co. Crosses Threshold at ABIVAX Voting Rights Capital Abivax Threshold Crossing JP Morgan
BRIEF published on 08/13/2025 at 18:05, 1 year 1 month ago ABIVAX: Update on capital and voting rights Euronext Paris Share Capital Voting Rights AMF Abivax
BRIEF published on 08/13/2025 at 18:05, 1 year 1 month ago ABIVAX: Share and voting rights data as of July 31, 2025 Euronext Paris Voting Rights Biotechnology Actions AMF Regulations
BRIEF published on 07/28/2025 at 22:20, 1 year 1 month ago Abivax Completes $747.5 Million Public Offering Biotechnology Abivax Ulcerative Colitis Nasdaq Public Offer
PRESS RELEASE published on 07/28/2025 at 22:15, 1 year 1 month ago Abivax Announces Closing of $747.5 Million Public Offering Abivax announces closing of $747.5 million public offering, enabling financing into Q4 2027 and reaching planned milestones for Ulcerative Colitis. ADSs listed on Euronext Paris and Nasdaq Global Market Abivax Ulcerative Colitis Nasdaq Finance Public Offering
BRIEF published on 07/25/2025 at 08:05, 1 year 1 month ago Abivax Raises $747.5M Through ADS Offering Biotechnology Abivax Nasdaq Capital Increase ADS Offering
Published on 09/17/2026 at 10:00, 9 minutes ago Eagle Plains Reports Additional Results from Drilling at the Don Lake Uranium Project, Saskatchewan
Published on 09/16/2026 at 23:45, 10 hours 24 minutes ago Galway Metals Settles Claim by Former Employee with Cash and Share Payments
Published on 09/16/2026 at 21:30, 12 hours 39 minutes ago Torq Completes $1.7 Million Private Placement
Published on 09/16/2026 at 16:55, 17 hours 14 minutes ago CORRECTION FROM SOURCE: SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/16/2026 at 15:00, 19 hours 9 minutes ago 2026 Canada's Top 40 Under 40(R) Honourees Announced
Published on 09/17/2026 at 09:49, 20 minutes ago Kirchhoff analysis: Most AGM speeches in the SDAX are overly complex and lack accessibility
Published on 09/17/2026 at 09:30, 39 minutes ago Allane Mobility Group and DEKRA expand their network of return locations
Published on 09/17/2026 at 09:28, 40 minutes ago KNDS THL20 TURRETS SELECTED FOR INDIA’S NEW LIGHT COMBAT HELICOPTER PROGRAM
Published on 09/17/2026 at 09:00, 1 hour 9 minutes ago Encavis completes EUR 282 million non-recourse project financing for 351 MW solar PV portfolio in Italy
Published on 09/16/2026 at 17:45, 16 hours 24 minutes ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 3 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 16 hours ago Report on the Combined General Meeting of the 10th of September 2026
